Evidence map›Paper›PMID 32821182›Full record

ArticleRisk management and healthcare policy2020

Presepsin Level Correlates with the Development of Moderate Coronary Artery Calcifications in Hemodialysis Patients: A Preliminary Cross-Section Design Study.

Ahmed F Elhabashi, Leena Sulaibeekh, Nahed Seddiq, Salman Alali, Amjad K Abdulmajeed, Nuria S Perez

Abstract read
In one paragraph

Article in Risk management and healthcare policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmed F ElhabashiBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.
Leena SulaibeekhBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.ORCID 0000-0002-3536-5486
Nahed SeddiqBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.
Salman AlaliBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.
Amjad K AbdulmajeedBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.
Nuria S PerezBahrain Defense Force Hospital, Royal Medical Services, Riffa, Kingdom of Bahrain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEnd-stage renal disease patients have a high mortality rate linked to cardiovascular complications, and one of these complications is vascular calcification. This study was performed to test if presepsin, an inflammatory marker, is a predictor of coronary artery calcification (CAC) in hemodialysis (HD) patients. PATIENTS AND

methodsThis study was a cross-sectional design involving 48 HD patients and 13 control subjects. Coronary artery calcification score (CACs) was evaluated by a high resolution, ECG synchronized computed tomography of the heart using a CT calcium scoring. Presepsin and other laboratory analyses were performed on blood samples drawn before HD.

resultsPresepsin levels in HD patients were 14 times higher than healthy controls (P<0.01). Also, all laboratory tests except for vitamin D were significantly different than controls. Presepsin, phosphorus levels, and calcium-phosphate product were positively correlated with increasing CACs within groups of zero to moderate calcifications (p<0.05, R=0.459 and <0.01, R=0.591, respectively). These correlations were not seen with eGFR, PTH, calcium, vitamin D, CRP, or ESR levels. Furthermore, the log-transformed data of presepsin correlated with 1-15 months of HD vintage (p<0.05, R=0.482), whereas CACs data correlated with 1-20 months of HD vintage (p<0.05, R=0.425).

conclusionAlthough this study is preliminary and has a limited number of patients, it shows that presepsin, as an inflammatory marker, correlates with the development of moderate CAC in HD patients and may predict CAC development. Therefore, measuring presepsin and managing inflammation before and during the early phases of HD may lower coronary calcification development. However, more clinical studies in this direction are essential.

Indexed as

coronary arterial calcificationend-stage renal diseasehemodialysispresepsin

Identifiers

PMID32821182
PMCPMC7422906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.